Lab Location: #7-17 Email: jeconnolly@imcb.a-star.edu.sg Tel: 65869652
Dr John Connolly is a Research Director for Translational Immunology at the Institute of Molecular and Cellular Biology (IMCB) A*STAR. Additionally, Dr Connolly serves as the Chief Scientific Officer of Parker Institute for Cancer Immunotherapy, a multi-disciplinary center focused on next generation therapy in immunooncology, Interim Chief Executive Officer (3T Biosciences in 2020 – July 2021), Scientific Cofounder (Twain Therapeutics), Board of Directors (3T Biosciences, Lyell Immunopharma), Scientific Advisor then Chief Scientific Officer (Tessa Therapeutics in 2012 – 2020).
As a human immunologist, his research interests focus on target discovery for immune modulation. An Adjunct Associate Professor of Immunology at Baylor University, he served on the Board of Governors for the Institute of Biomedical Sciences.
Dr Connolly received his Ph.D. in Immunology from Dartmouth Medical School and studied human dendritic cell biology under Dr Michael Fanger. During this time he was involved in the development of immunotherapeutic preclinical models and clinical trials for Glioblastoma multiforme (GBM). He moved to the Baylor Institute for Immunology Research, a fully translational research institute dedicated to rationally designed vaccines against cancer and infectious disease. Dr Connolly served as the Director of Research Initiatives for the Baylor Research Institute, leading a large integrated translational research resource and multi-institutional programs that involved a number of international sites. During his tenure at Baylor, Dr Connolly was a central core facility director of the NIAID Centers for Translational Research on Human Immunology and Biodefense, an NIH funded consortium of basic, translational research and clinical trials focused on vaccine design. Dr. Connolly is the past President of the Board of Directors of The American Cancer Society in N. Texas and founding Director of the Singapore Immunology Network’s Immunomonitoring Platform.
MAIN APPOINTMENT
o Chief Industry Officer, Institute of Molecular and Cell Biology, A*STAR
o Research Director, Institute for Molecular and Cell Biology, A*STAR
o Director, Programme in Translational Immunology
o Chief Scientific Officer, Parker Institute for Cancer Immunotherapy
o Interim Chief Executive Officer, 3T Biosciences (2020 – July 2021)
o Scientific Cofounder,Twain Therapeutics
o Board of Directors, 3T Biosciences
o Board of Directors, Lyell Immunopharma
RESEARCH FOCUS
o Synthetic biology
o Immunotherapy
o CAR T
o Cell therapy
o Bioreactor
o Immune monitoring
o Immunometabolism
o Myeloid suppression
o Solid tumor biology
o Novel vector platforms
|